Anti-Human VEGF Therapeutic Antibody (Bevacizumab)
Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian. Bevacizumab is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-011 |
| Pricing | Inquiry |
| Host | Mouse |
| Target | VEGF |
| Species Reactivity | Human |
| Type | IgG1 - kappa |
| Applications | Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, ICC and most other immunological methods. |
| Storage | Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples. |